Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders

The approved standard dose of pazopanib is 800 mg per day, but the appropriate dose of pazopanib to treat soft tissue sarcoma (STS) patients in real-world practice is controversial. Of 124 STS patients treated with pazopanib, we retrospectively analyzed the cases of STS patients who achieved progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Kenji, Funauchi, Yuki, Hayakawa, Keiko, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352274/
https://www.ncbi.nlm.nih.gov/pubmed/30626115
http://dx.doi.org/10.3390/jcm8010060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352274/
https://www.ncbi.nlm.nih.gov/pubmed/30626115
http://dx.doi.org/10.3390/jcm8010060

Ejemplares similares